bullish
HK Inno.N (INNO KS): On a Solid Growth Path with Blockbuster New Drug K-CAB
Tina has highlighted this Insight as a Top Pick
435 Views19 Nov 2021 17:46
SUMMARY
- HK inno.N (INNO KS)'s new digestive disease drug K-CAB is the only drug of its class available in Korean market and has superior efficacy than the current standard of care.
- K-CAB has already become the no. 1 drug in Korean digestive treatment market. HK inno plans to further strengthen its position by expanding global presence and increasing indication approvals.
- From this year, HK inno has started distributing Merck’s seven vaccines, including its largest selling HPV vaccine 'Gardasil' in Korea. The company also has a rich pipeline of innovative drugs.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- HK Inno.N (195940 KS): 2024 Will See Robust Profit Growth On Growing Momentum of Key Drug23 Apr 2024
- HK Inno.N (195940 KS): 2Q23 Result Shows Strong Sequential Improvement; K-CAB Continues to Fly High03 Aug 2023
- HK Inno. N (195940 KS): Flagship Drug K-CAB Is Set to Become a Global Blockbuster Drug23 May 2022
- HK Inno.N Post-Listing Immediate Float Analysis05 Aug 2021
- HK Inno.N (Formerly CJ Healthcare) IPO: Offering Detail & Valuation Issues07 Jul 2021
- HK Inno.N IPO Valuation Analysis05 Jul 2021
x